FGFR2 mutations are rare across histologic subtypes of ovarian cancer (Q42813018)

6

0 references

author name string

Michael G Gartside

2

1 reference

7 November 2017

Candice L Wellens

3

1 reference

7 November 2017

Paul J Goodfellow

4

1 reference

7 November 2017

Michael J Birrer

describes a project that uses

5

1 reference

7 November 2017

language of work or name

English

0 references

publication date

27 January 2010

1 reference

7 November 2017

1 reference

7 November 2017

117

1 reference

7 November 2017

125-129

1 reference

7 November 2017

1

1 reference

7 November 2017

SW626

0 references

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Mutation of the PIK3CA gene in ovarian and breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Fibroblast growth factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Structural basis for fibroblast growth factor receptor activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Ovarian surface epithelium: biology, endocrinology, and pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Expression of fibroblast growth factor (FGF)-8 isoforms and FGF receptors in human ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Ligands to FGF receptor 2-IIIb induce proliferation, motility, protection from cell death and cytoskeletal rearrangements in epithelial ovarian cancer cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Patterns of somatic mutation in human cancer genomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Drug-sensitive FGFR2 mutations in endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

De novo alu-element insertions in FGFR2 identify a distinct pathological basis for Apert syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Rare mutations of FGFR2 causing apert syndrome: identification of the first partial gene deletion, and an Alu element insertion from a new subfamily

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

FGFR activation in skeletal disorders: too much of a good thing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Expression and action of keratinocyte growth factor (KGF) in normal ovarian surface epithelium and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis gyrata syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002

Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.002